A new pancreatic cancer drug is generating cautious optimism among physicians and researchers who have long battled one of the deadliest cancers known to medicine. The drug, which targets a gene at the heart of pancreatic cancer, has shown results that experts are calling extraordinary, and even unprecedented, raising hope for patients who have historically faced grim odds.

With detailed Phase 3 data now public, the medical community is paying close attention to what could be a turning point in how this devastating disease is treated.

Meet Daraxonrasib

The drug at the center of this excitement is called daraxonrasib, developed by the pharmaceutical company Revolution Medicines. Taken as a once-daily pill, it belongs to a class of drugs known as RAS inhibitors that target the KRAS gene.

That gene is a major culprit across multiple cancers. Mutations of KRAS are found in more than 90% of patients with the most common type of pancreatic cancer, as well as in 40 to 45% of colorectal cancer patients and up to 30% of people with non-small cell lung cancer. This broad relevance is part of what makes the drug so promising.

Why Pancreatic Cancer Is So Deadly

To understand the significance of this development, it helps to grasp just how lethal pancreatic cancer can be. The disease is notoriously difficult to detect early and ranks among the hardest cancers to treat.

The numbers are sobering. Once the cancer has spread to other parts of the body, the five-year survival rate drops to only 3%, and the vast majority of patients are diagnosed only after the disease has reached an advanced stage. Against this backdrop, even modest improvements in survival represent meaningful progress.

“Unprecedented” Phase 3 Results

The latest data have exceeded the hopes raised by earlier trials. Revolution Medicines announced detailed results from the global, randomized Phase 3 RASolute 302 clinical trial evaluating daraxonrasib in patients with previously treated metastatic pancreatic ductal adenocarcinoma, presented at the 2026 American Society of Clinical Oncology Annual Meeting and published in The New England Journal of Medicine. Revolution Medicines

The headline finding is striking. In this trial, daraxonrasib reduced the risk of death by 60% and increased median overall survival to more than one year, a result not previously reported in any Phase 3 clinical trial in any line of therapy for this disease. Revolution Medicines

Digging into the specifics, the trial of roughly 500 patients showed that daraxonrasib demonstrated a median overall survival of 13.2 months versus 6.7 months for chemotherapy, with a hazard ratio of 0.40. In effect, the drug nearly doubled survival time compared with standard chemotherapy. Revolution Medicines

Benefits Beyond Survival Time

The advantages extended past sheer longevity. According to the trial findings, all primary and key secondary endpoints were met, and the quality of patients’ remaining time also improved.

Notably, patients treated with daraxonrasib reported significantly delayed deterioration in cancer-related pain, overall global health status, and quality of life, compared to those treated with chemotherapy. For a disease that often brings significant suffering, this aspect may prove just as important as the survival gains. Revolution Medicines

A Drug That Works Broadly

One of the most intriguing aspects of daraxonrasib is that its benefits do not appear limited to patients with a specific mutation. The drug demonstrated improvements in patients with previously treated metastatic PDAC, with or without an identified tumor RAS mutation. Revolution Medicines

The principal investigator on the trial captured the implication plainly, noting that based on the current data, the drug appears relevant to essentially all patients with metastatic pancreatic cancer, regardless of their KRAS status. This versatility means physicians may not need to screen each patient for a particular mutation before prescribing it.

Cracking the “Undruggable” Target

The story of how daraxonrasib came to be is itself a remarkable scientific journey. The KRAS gene, present in as much as 20% or more of all cancers, was long considered “undruggable” for decades.

Several factors made it so challenging:

• The gene’s smooth structure offered few places for proteins to bind.
• KRAS sits inside the cell rather than on its surface, requiring a drug that could penetrate the cell.
• When dysregulated, KRAS constantly overstimulates the cell it inhabits, driving cancerous growth.

The breakthrough came in 2013, when scientists identified a small, previously unknown pocket in KRAS. Pharmaceutical companies then collaborated with universities and investigators to develop drugs capable of binding to that pocket, an advance that one expert said simply “opened up the whole field.”

A Shift From “Death Sentence”

For the oncologists who have spent careers fighting this disease, the change in outlook is profound. One Johns Hopkins oncology professor reflected that, for all the years she has treated and developed therapies for pancreatic cancer, it has remained a death sentence.

Chemotherapy, which can be difficult to tolerate, often grants patients only a few additional months, and even cancers deemed curable may return. By contrast, daraxonrasib has been described as having manageable toxicities compared with chemotherapy, offering a more bearable path for many patients.

The Side Effects and Drawbacks

The drug is not without challenges. Earlier data indicated that severe side effects occurred in about 30% of patients, with around 90% experiencing a rash and roughly half facing diarrhea or inflammation of the mouth or GI tract. The once-daily pill’s side effects can also include nausea, vomiting, and fatigue.

Beyond the physical toll, several practical concerns remain:

• Access is currently limited. While the FDA granted expanded access for eligible patients, most doctors do not yet have the drug available, and since much cancer care happens in community settings rather than large university centers, this could create equity issues.
• Cost is uncertain. The price has not been set, and because the drug is taken daily, patients may need hundreds of pills. Oral targeted therapies have historically run into the tens of thousands of dollars per month, with insurance coverage often difficult to secure.
• Oral administration assumes patients can swallow and digest medication, which is not always possible for those with advanced cancer.

Regulatory Momentum

The drug is moving quickly through the approval pipeline. The FDA has granted daraxonrasib breakthrough therapy designation and orphan drug designation for previously treated metastatic PDAC harboring G12 mutations, and it has been selected for the FDA Commissioner’s National Priority Voucher pilot program.

Revolution Medicines has stated that it intends to submit a New Drug Application to the FDA under this expedited pathway and to file data with other global regulatory authorities, signaling an urgent push to get the therapy to patients.

What Comes Next

The future direction of daraxonrasib extends well beyond its current use. Experts hope the drug, and others in its class, could eventually be used earlier in the treatment process, or potentially alongside targeted immunotherapy or surgery, which may improve both the length and quality of patients’ lives.

Encouragingly, early research suggests the drug shows first-line activity, both on its own and in combination with chemotherapy, producing outcomes that exceed historical benchmarks. Revolution Medicines has also indicated it has several other RAS inhibitors in clinical trials, hinting at a broader pipeline of related therapies.

A Glimpse of a Different Future

Perhaps the most hopeful framing comes from the comparison some researchers draw to HIV. Once a fatal diagnosis, HIV became manageable after scientists discovered treatments, identified how the disease resisted them, and developed combinations of drugs targeting multiple pathways at once.

With daraxonrasib, experts believe they have hit the first component of pancreatic cancer’s key pathway. The next step will be figuring out effective combinations, a more complex undertaking, but one where significant work is already underway.

The new pancreatic cancer drug does not represent a cure, and important questions about access, cost, and long-term outcomes remain. Yet for a disease that has resisted progress for so long, the doubling of survival time and the prospect of a more tolerable treatment mark a genuine and hard-won advance. For patients and physicians alike, daraxonrasib offers something that has been in short supply when it comes to pancreatic cancer: real, evidence-backed hope.

This article discusses a serious illness and its treatment. It is meant for general information and is not a substitute for medical advice. Anyone facing decisions about cancer treatment should consult their own physician, who can account for the specifics of their situation.